Biosimilars Shake Off Doubters, Go on a Roll

Area of Science:

• Biopharmaceutical science
• Regulatory affairs

Background:

• The U.S. Food and Drug Administration (FDA) has approved seven biosimilar products.
• The FDA's abbreviated pathway for biosimilar approval has remained consistent.
• International regulatory bodies are increasingly adopting and understanding the FDA's approach.

Purpose of the Study:

• To review the FDA's approval process for biosimilars.
• To highlight the criteria used for biosimilar evaluation.
• To discuss the global convergence in biosimilar regulatory standards.

Main Methods:

• Analysis of FDA approval data for biosimilars.
• Review of regulatory guidelines and statements regarding biosimilarity.
• Assessment of the evidence base required for biosimilar approval.

Main Results:

• Seven biosimilars have successfully navigated the FDA approval process.
• The FDA's abbreviated pathway has been consistently applied.
• Global regulatory agencies are demonstrating a greater understanding of the FDA's framework.
• Approval decisions emphasize a "totality of evidence" approach, including analytic similarity and clinical performance, with reduced reliance on Phase 3 trials.

Conclusions:

• The FDA's established pathway facilitates biosimilar approvals.
• A comprehensive evidence-based approach, prioritizing analytic similarity and clinical data, is key to biosimilar evaluation.
• Increasing global alignment on regulatory standards promotes biosimilar market development.